Key Takeaways AU surged 23.1% since its May upgrade to Zacks Rank #1, beating the S&P 500s 7.2% increase in that span.CAT advanced 41.3% in 12 weeks as a Zacks Focus List stock, far outpacing the S&P 500s 15.7% gain.HSY climbed 17.8% in 12 weeks as part of Zacks dividend-focused ECDP portfolio.The U.S. markets continued their upward trajectory over the past week, with the S&P 500 and Nasdaq Composite closing at fresh all-time highs. The three widely followed U.S. indexes — the Nasdaq Composite, the Dow Jone ...

The market expects Mettler-Toledo (MTD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Mettler-Toledo (MTD) , which belongs to the Zacks Medical - Instruments industry.This maker of precision instruments has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 4.91%.For the most recent quarter, Mettler-Toledo was expected to ...

Market Overview - The three major U.S. stock indexes closed lower last week, with the Dow Jones Industrial Average down 1%, the S&P 500 down 0.3%, and the Nasdaq Composite down 0.1% [1] - The market pullback was influenced by renewed U.S. tariff threats, particularly higher levies on Canada and the European Union, raising concerns about economic growth and inflation [2] Earnings Performance - Despite tariff concerns, many investors focused on strong earnings reports from airlines and consumer stocks, indicating a resilient economy [2] - The second-quarter earnings season is critical for assessing the impact of tariffs on corporate profits [3] Zacks Research Performance - Mogo Inc. shares surged 81.8% since being upgraded to Zacks Rank 2 (Buy) on May 8, significantly outperforming the S&P 500's 11.1% increase [4] - ATI Inc. also saw a 32.6% return since its upgrade to Zacks Rank 2 on May 6, compared to the S&P 500's 10.7% increase [5] - A hypothetical portfolio of Zacks Rank 1 (Strong Buy) stocks returned +6.51% in May 2025, outperforming the S&P 500's +4.47% [5] Zacks Recommendations - Amarin Corporation and European Wax Center shares increased by 62.6% and 49.9%, respectively, after being upgraded to Outperform on May 12, against the S&P 500's 10.5% rise [8] - The Zacks Focus List portfolio returned 8.84% in 2025 (through June 30) compared to the S&P 500's +6.21% [12] Portfolio Performance - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned +3.20% in Q1 2025, outperforming the S&P 500's -4.30% decline [16] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in Q1 2025, compared to the S&P 500's -2.41% [20] - The Zacks Top 10 Stocks portfolio delivered +11.8% year-to-date through June 2025, outperforming the S&P 500's +6.2% [22] Long-term Performance - Since 2004, the Zacks Focus List portfolio has produced an annualized return of +11.60%, compared to +10.22% for the S&P 500 [15] - The Top 10 portfolio has generated a cumulative return of +2,246.8% since 2012, significantly outperforming the S&P 500's +502.3% [24]

Core Viewpoint - The revenue of multinational instrument companies in China has generally declined in 2024, with only Merck achieving growth, while many companies have experienced consecutive declines over the past two years due to multiple factors including US-China trade tensions, economic environment, and market competition [1][2]. Revenue Performance Summary - In 2024, Merck led the revenue rankings in China with $32.98 billion, marking a 5.8% increase after a 14.2% decline in 2023 [5][6]. - Danaher followed with $28.05 billion, down 10.8%, continuing a downward trend from $31.43 billion in 2023, which was a 13.0% decrease [6][8]. - Agilent ranked third with $12.20 billion, a decline of 11.6%, following a 7.9% drop in 2023 [7][8]. - Shimadzu and Mettler-Toledo ranked fourth and fifth with revenues of $6.30 billion and $6.22 billion, respectively, both experiencing declines [8]. - Overall, over 80% of the listed companies saw a year-on-year revenue decrease in 2024, with some companies facing declines for two consecutive years [8][14]. Market Share Analysis - The market share of many companies in China has also shown a downward trend, reflecting poor performance and indicating a relative decline in market vitality compared to global markets [9]. - In 2024, Agilent's market share in China was 18.74%, down from over 20% in previous years, indicating a significant drop [9]. Company-Specific Insights - Danaher reported that approximately 12% of its sales come from China, highlighting the potential adverse effects of the political, economic, and regulatory environment on its business [11]. - Waters experienced a notable 30% decline in sales in China, attributed to decreased demand across various customer categories due to economic conditions and trade tensions [12]. - Agilent's revenue decline was primarily driven by pressures in capital spending from clients, particularly in the pharmaceutical market [12]. - Mettler-Toledo emphasized the importance of the Chinese market, which accounted for 16% of its external sales, and noted the impact of geopolitical tensions and economic pressures on its performance [13]. Strategic Adjustments - In response to market changes, multinational companies are accelerating strategic adjustments, increasing investment in local R&D, and launching products tailored to local needs [15]. - Despite the challenges faced from 2022 to 2024, the long-term potential of the Chinese market remains significant, and companies are expected to adapt more flexibly and innovatively to maintain competitiveness [15].

Group 1 - Berkshire Hathaway's See's Candies and Mettler-Toledo (MTD) appear unrelated at first glance, but both companies may share some operational synergies [1] - The article reflects a long-term investment philosophy, emphasizing the importance of knowledge compounding and strategic thinking in investment [1] Group 2 - The author has a beneficial long position in MTD shares, indicating a personal investment interest in the company [2] - The article is a personal opinion piece, with no external compensation influencing the views expressed [2]

应用工程师 石化行业-成都- 2 5 - 3 5 k . 1 3薪 安东帕(上海)商贸有限公司 销售工程师（微波光学） 南京-面议 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪粉e r们，今天2 0 2 4年杰出雇主专辑： 加入 内推求职群 ，小谱君和仪小职会在群里为大家 内推简历 哦！ 先Po一波 杰出雇主职位 （奖项在职位后）： 安捷伦科技(中国)有限公司 北京莱伯泰科仪器股份有限公司 销售工程 师 合肥- 8 k - 1 2 k · 1 3薪 北京东西分析仪器有限公司 销售工程师 北京- 6 k - 8 k · 1 2薪 湖南力辰仪器科技有限公司 外贸负责人 青岛- 1 2 k - 2 0 k · 1 3薪 梅特勒托利多 软件测试实习生 上海-面议 牛津仪器科技（上海）有限公司 Na n o -I n d e n t e r BD 纳米压痕仪业务拓展经理 上海-面议 青岛盛瀚色谱技术有限公司 昆明-面议 天美仪拓实验室设备（上海） 有限公司 实验室产品销售 产品经理（离子色谱耗材） 青岛- 8 k - 1 5 k · 1 ...

Summary of Mettler-Toledo International (MTD) Conference Call Company Overview - **Company**: Mettler-Toledo International (MTD) - **Date of Conference**: May 14, 2025 - **Speaker**: Sean Vidalia, Chief Financial Officer Key Points Financial Performance - **1Q Results**: MTD reported a 3% growth in underlying business, excluding shipping delays [3][4] - **Lab Business Growth**: Mid single-digit growth, with process analytics business growing just under 10% [3][4] - **Product Inspection**: Grew by 8%, indicating strong execution and new product introductions [4][5] - **Liquid Handling Business**: Experienced slight decline, affected by small biotech and academia sectors [4] Fiscal Year 2025 Guidance - **Tariff Impact**: Adjusted top-line guidance due to trade war uncertainties, with a 2% reduction in EPS guidance [6][8] - **Tariff Costs**: Estimated gross tariff headwind of $115 million annually, translating to a 7% headwind to EPS [11][12] - **China Tariff Changes**: Anticipated benefits from temporary de-escalation of tariffs, with a potential 3.5% EPS benefit [11][16] Market Dynamics - **China Market Outlook**: Initial expectations of low single-digit growth revised to slight decline; however, potential for future growth remains [28][32] - **Emerging Markets**: Growth in Southeast Asia, India, and Eastern Europe, now representing 18% of MTD's business, surpassing China [33][34] - **Academic and Government Sector**: Low single-digit percentage of global business; softness noted in both consumables and instruments [37][39] Biopharma and Process Analytics - **Bioprocessing**: Strong performance in process analytics, particularly with single-use technologies [42][45] - **Life Sciences Exposure**: Comprises about 40% of MTD's business, with a focus on production and QA/QC labs [46] Industrial Sector - **Core Industrial Business**: Represents 25% of MTD's business; guidance for flattish growth due to economic softness [49][50] - **Chemicals Sector**: Noted as softer relative to other end markets, indicating cyclicality [51] Reshoring and Supply Chain - **Reshoring Trends**: Companies are adopting "China plus one" strategies, diversifying supply chains to include emerging markets [35][36] - **Automation Demand**: Increased focus on automated solutions as companies seek productivity amidst rising costs [58][59] Margin Expansion Opportunities - **P&L Levers**: Continuous improvement culture, innovation, and pricing strategies are key to margin expansion [62][64] - **Cash Flow**: Strong cash flow conversion at approximately 100% [65][66] Underappreciated Aspects - **Diversity of Solutions**: MTD's ability to provide solutions across the entire value chain is a significant strength, especially in the context of reshoring [66] Additional Insights - **Market Uncertainty**: Ongoing uncertainties in the market, particularly regarding China, will be closely monitored for future guidance updates [27][29] - **Long-term Growth**: Despite current challenges, MTD remains optimistic about future growth opportunities in various sectors [32][33]

Core Viewpoint - Mettler-Toledo International (MTD) reported strong first-quarter 2025 results, with a positive outlook driven by growth in the laboratory business and recent innovations, despite a year-over-year decline in earnings and sales [1][2]. Financial Performance - Adjusted earnings for Q1 2025 were $8.19 per share, exceeding the Zacks Consensus Estimate by 3.67%, although this represents a 7.9% decline year-over-year [1]. - Net sales reached $883.744 million, surpassing the Zacks Consensus Estimate by 1%, but declined 5% on a reported basis and 3% on a local currency basis compared to the previous year [2]. Segment Performance - MTD's revenues were categorized into three segments: Laboratory Instruments ($500 million, 56.6% of net sales), Industrial Instruments ($341 million, 38.6%), and Food Retail ($42 million, 4.8%) [3]. - The Laboratory and Industrial segments experienced a year-over-year decline of 3% and 1% respectively in local currency, while the Food Retail segment saw a 12% decrease [3]. Geographic Sales Breakdown - Sales distribution included $378 million (42.8%) from the Americas, $248 million (28.1%) from Europe, and $258 million (29.2%) from Asia/Rest of the World [4]. - Year-over-year sales in the Americas and Asia/Rest of the World declined by 1% and 2% respectively, while Europe experienced a 7% decline [4]. Operating Results - The gross margin improved to 59.6%, an increase of 40 basis points year-over-year [5]. - Research & development (R&D) expenses were $46.3 million, a slight decrease of 0.1% from the previous year, while selling, general & administrative (SG&A) expenses rose by 3.6% to $242.8 million [5]. - The adjusted operating margin was reported at 26.8%, down 210 basis points from the prior year [6]. Balance Sheet & Cash Flow - As of March 31, 2025, Mettler-Toledo had cash and cash equivalents of $64.291 million, an increase from $59.362 million at the end of 2024 [7]. - Long-term debt stood at $1.89 billion, with cash generated from operating activities at $194.5 million, down from $266.2 million in the previous quarter [7]. Future Guidance - For Q2 2025, Mettler-Toledo expects sales to increase by 0-1% in local currency compared to the previous year, with adjusted earnings projected between $9.45 and $9.70 per share, reflecting a growth rate of down 2% to up 1% [8]. - The Zacks Consensus Estimate for Q2 revenues is $949.6 million, indicating a year-over-year increase of 0.3%, while the consensus for earnings is $10.22 per share, representing a 5.91% increase from the previous year [9]. - For the full year 2025, Mettler-Toledo anticipates a sales increase of approximately 1% to 2% in local currency compared to 2024, with adjusted earnings expected between $41.25 and $42 per share, indicating 0-2% growth [10].

Financial Performance - Net sales for the three months ended March 31, 2025, were $883.7 million, a decrease of 5% compared to $925.9 million in the same period of 2024[90] - Net earnings for the three months ended March 31, 2025, were $163.6 million, down from $177.5 million in the same period of 2024, reflecting a decrease in earnings before taxes[90] - Total net sales decreased 19% in U.S. dollars and 17% in local currency for the three months ended March 31, 2025 compared to the same period in 2024[114] - Net sales to external customers decreased 13% in U.S. dollars and 11% in local currency for the three months ended March 31, 2025 compared to the same period in 2024[114] - Total net sales decreased 10% in U.S. dollars and 8% in local currencies during the three months ended March 31, 2025 compared to the same period in 2024[117] Profitability and Expenses - Gross profit margin increased to 59.5% for the three months ended March 31, 2025, compared to 59.2% in the corresponding period in 2024, driven by favorable price realization[103] - Research and development expenses were $46.3 million, representing 5.2% of net sales, compared to 5.0% in the same period of 2024[106] - Selling, general and administrative expenses increased to $242.8 million, or 27.5% of net sales, up from 25.3% in the prior year[107] - Segment profit for U.S. Operations decreased by $9.3 million to $84.3 million for the three months ended March 31, 2025, impacted by lower sales volume and higher expenses[113] - Segment profit decreased by $7.3 million for the three-month period ended March 31, 2025 compared to the same period in 2024[118] Regional Sales Performance - Net sales in the Americas decreased by 2%, while Europe saw a 9% decline, and Asia/Rest of World experienced a 4% decrease in U.S. dollars for the three months ended March 31, 2025[96] - In Western European Operations, net sales to external customers decreased by 11% to $190.4 million for the three months ended March 31, 2025 compared to $214.8 million in 2024[116] Cash Flow and Capital Management - Cash provided by operating activities totaled $194.4 million during the three months ended March 31, 2025, compared to $190.0 million in the same period in 2024[129] - Capital expenditures totaled $17.3 million for the three months ended March 31, 2025 compared to $17.4 million in the same period in 2024[130] - As of March 31, 2025, approximately $679.8 million of additional borrowings was available under the Credit Agreement[132] - The company has $1.5 billion of remaining availability for its share repurchase program as of March 31, 2025[137] - The company has repurchased 32.5 million common shares at an average price of $307.74 since the program's inception in 2004 through March 31, 2025[138] - In Q1 2025, the company spent $218.7 million to repurchase 170,957 shares at an average price of $1,279.54, compared to $212.5 million for 173,700 shares at $1,223.35 in Q1 2024[138] Tax and Currency Impact - The company incurred $2.0 million and $2.1 million in excise tax during Q1 2025 and 2024, respectively, related to the Inflation Reduction Act[138] - A 1% strengthening of the Swiss franc against the euro is estimated to reduce earnings before tax by approximately $2.4 million to $2.7 million annually[139] - A 1% weakening of the Chinese renminbi against the U.S. dollar is estimated to reduce earnings before tax by approximately $2.2 million to $2.5 million annually[140] - A 5% weakening of the U.S. dollar against the currencies in which the company's debt is denominated would result in an increase of approximately $47.6 million in the reported U.S. dollar value of the debt[141] Risks and Uncertainties - The company expects gross margin to be negatively impacted by the recent escalation in global trade disputes and tariffs throughout 2025[105] - The company cautions that actual results may differ materially from forward-looking statements due to various risks and uncertainties, including global trade disputes and inflation[142] - There was no material change in market risk information as of March 31, 2025, compared to the previous annual report[144]